Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Johnson & Johnson Relinquishes Top Spot To Eli Lilly, Shares Undervalued Amid Technical Risks
01:23pm, Thursday, 08'th Jun 2023
Eli Lilly has surpassed Johnson & Johnson in market cap for the first time, driven by LLY's breakthroughs in obesity and Alzheimer's treatments. JNJ features a relatively less sanguine pipeline and ea
7 Growth Stocks to Sell in June Before They Crash and Burn
08:48pm, Monday, 05'th Jun 2023
Figuring out which growth stocks to sell may be the last thing on your mind right now. After all, rising hopes for a pivot on interest rates by the Federal Reserve, plus secular growth trends such as
Buy These 3 Top-Ranked ETFs and Never Sell
05:55pm, Friday, 02'nd Jun 2023
Investors seeking long-term growth and diversification often turn to Exchange-Traded Funds (ETFs) as a reliable investment option. With their unique advantages, ETFs have gained popularity among both
Eli Lilly releases new data on breast cancer, lymphoma treatments
08:03am, Friday, 02'nd Jun 2023
Eli Lilly & Co. LLY, +1.64% on Friday released new clinical trial data on treatments for certain types of early breast cancer and mantle cell lymphoma. New analysis from a late-stage trial of Verzenio
Medicare unveils plan for coverage of new Alzheimer's drugs
01:44pm, Thursday, 01'st Jun 2023
Medicare on Thursday announced plans for coverage of new Alzheimer's drugs whose accessibility has become a point of controversy.
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
12:17pm, Thursday, 01'st Jun 2023
Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
10:04am, Thursday, 01'st Jun 2023
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Lilly to Participate in Goldman Sachs Global Healthcare Conference
10:00am, Tuesday, 30'th May 2023
INDIANAPOLIS , May 30, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 44th Annual Global Healthcare Conference, June 12-13, 2023. Anat Ashkenazi, Lilly executive
Better Dividend Stock: Eli Lilly or Novo Nordisk?
08:45am, Tuesday, 30'th May 2023
Eli Lilly and Novo Nordisk have been two of the hottest dividend-paying pharma stocks of late. While both companies sport well-supported dividends, one company comes with inherently less risk and stro
Sequoia China-Backed AI Startup Xtalpi To Partner With Pharma Giant Eli Lilly In $250 Million Novel Drug Deal
08:00am, Tuesday, 30'th May 2023
XtalPi said the drug candidates will target a disease that currently has no medicine available.
This Pharma's Sales Are So Hot It's Trying to Curb Demand
05:15am, Tuesday, 30'th May 2023
Novo Nordisk is struggling to keep up with demand for Wegovy. It's experiencing manufacturing problems and delaying new-patient starts.
7 Overvalued Value Stocks to Sell Before June 2023
06:27pm, Sunday, 28'th May 2023
No, you read this correctly – we're here to discuss overvalued value stocks to sell. Seemingly a contradiction in terms, a company that becomes overvalued by nature is no longer a value play.
3 High-Growth Stocks to Buy Before They Join the Trillion-Dollar Club
02:04pm, Saturday, 27'th May 2023
The trillion-dollar club is an exceedingly rare group. In fact, there are only 5 companies on that list currently.
Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected
12:17pm, Friday, 26'th May 2023
An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine. The post Eli Lilly Could Launch Its Rival To Novo Nordisk's
The dark side of the weight-loss drug craze: Eating disorders, medication shortages, dangerous knock-offs
10:04am, Friday, 26'th May 2023
A national obsession with a new class of weight-loss drugs is turning dangerous, doctors and researchers say, as many patients are inappropriately prescribed Wegovy, Ozempic and similar medications an
